PAX8 and ovarian cancer: In addition, due to the enriched expression of PRDM3 in ovarian cancer cells, we validated that PRDM3 alone can interact with PAX8 by co-immunoprecipitation of ectopically expressed PAX8 and PRDM3 in HEK293 cells (Fig. 1E), as well as by complementation assay using a cellular NanoBit assay (Fig. 1F).